Ex-Vivo and In-Vitro Evidence that Low Molecular Weight Heparins Exhibit Less Binding to Plasma Proteins than Unfractionated Heparin

We have compared the non-specific binding of unfractionated heparin (UFH) with that of low molecular weight heparin (LMWH) to plasma proteins both ex-vivo and in-vitro. Non-specific binding to plasma proteins was assessed by comparing the heparin levels measured as anti-factor Xa activity before and after the addition of low affinity heparin, which is essentially devoid of anti-factor Xa activity, in order to displace heparin bound to plasma proteins. For the ex-vivo studies, we compared the recovery of UFH and a LMWH (ardeparin) from the plasma of patients participating in a randomized trial of post-operative venous thrombosis prophylaxis. For the in-vitro studies, we compared the recovery of UFH and 4 different LMWHs when added to the plasma from healthy volunteers and from patients with suspected venous thromboembolic disease. The results indicate that the recovery of LMWH is much less affected by nonspecific binding to plasma proteins both ex-vivo and in-vitro. In addition, there are differences between the LMWHs with respect to their plasma protein-binding.

[1]  J. Hirsh,et al.  Comparison of the Non-Specific Binding of Unfractionated Heparin and Low Molecular Weight Heparin (Enoxaparin) to Plasma Proteins , 1993, Thrombosis and Haemostasis.

[2]  J. Hirsh.  Low molecular weight heparin , 2007 .

[3]  M. Prins,et al.  Heparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance , 1992, Thrombosis and Haemostasis.

[4]  G. Raskob,et al.  Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. , 1992, The New England journal of medicine.

[5]  H. Büller,et al.  Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis , 1992, The Lancet.

[6]  R. Conroy,et al.  Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. , 1991, The Journal of clinical investigation.

[7]  J. Hirsh,et al.  A standard heparin nomogram for the management of heparin therapy. , 1991, Archives of internal medicine.

[8]  J. Hirsh.  Drug therapy : heparin , 1991 .

[9]  J. Hirsh,et al.  Contribution of Red Blood Cells to the Saturable Mechanism of Heparin Clearance , 1990, Thrombosis and Haemostasis.

[10]  K. Mayo,et al.  Human Platelet Factor 4 and Its C-Terminal Peptides: Heparin Binding and Clearance from the Circulation , 1990, Thrombosis and Haemostasis.

[11]  M. Samama,et al.  The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg , 1988, Journal of clinical pharmacology.

[12]  K. Preissner,et al.  Neutralization and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin-binding domain of S protein/vitronectin. , 1987, The Journal of biological chemistry.

[13]  G. Raskob,et al.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. , 1986, The New England journal of medicine.

[14]  G. Bratt,et al.  Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. , 1986, Thrombosis research.

[15]  D. Bergqvist,et al.  Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. , 1986, Haemostasis.

[16]  M. Samama,et al.  Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. , 1985, Thrombosis research.

[17]  M. Petitou,et al.  Binding and endocytosis of heparin by human endothelial cells in culture. , 1985, Biochimica et biophysica acta.

[18]  M. Hoylaerts,et al.  Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. , 1983, The Journal of biological chemistry.

[19]  M. Mosesson,et al.  The structure and biologic activities of plasma fibronectin. , 1980, Blood.

[20]  Laurell Cb,et al.  The interaction of heparin with plasma proteins. Demonstration of different binding sites for antithrombin III complexes and antithrombin III. , 1980 .

[21]  M. L. Larsen,et al.  Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). , 1978, Thrombosis research.

[22]  M. Lie,et al.  Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. , 1977, Thrombosis research.

[23]  R. J. Tuttle,et al.  Small subcutaneous doses of heparin in prevention of venous thrombosis. , 1973, The New England journal of medicine.